At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 13 enrolled
Drug / intervention
Avacopandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Avacopan in Subjects With Normal Renal Function and Subjects With End-Stage Renal Disease (ESRD) Requiring Hemodialysis
In Brief
A Phase 1 clinical trial evaluating Avacopan for End-Stage Renal Disease (ESRD). Completed, enrolled 13 participants across 2 sites.
Detailed Summary
The primary objective of the study is to evaluate the pharmacokinetics (PK) of avacopan and metabolite (M1) after a single dose of avacopan in participants with normal renal function and participants with ESRD requiring hemodialysis (HD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd-Stage Renal Disease (ESRD)
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20252026
Enrollment StartJun 2024
First PostedJun 2024
Primary CompletionOct 2024
TodayJul 2026
First PostedJun 21, 2024
Enrollment StartJun 18, 2024
Primary CompletionOct 5, 2024
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 2.0 years ago
Interventions
Avacopandrug
Oral capsules